Composition & Format Peptide: CJC-1295 With DAC Strength options: 2 mg or 5 mg per vial (variable product) Kit configuration: 10 vials/kit 20 mg or 50 mg total peptide per kit Form: white lyophilized peptide powder in crimp-sealed vials Origin: China-based peptide factory with OEM and bulk supply capability Key Features for Wholesale Buyers High-purity (99%) CJC-1295 DAC suitable for advanced peptide research panels Factory-direct supply from a specialised peptide manufacturer in China Stable lyophilized format for international shipping and long-term storage Flexible order structure: standard 10-vial kits, with bulk and OEM packing on request Technical documents (COA / HPLC data) can be provided for qualifying bulk orders Packaging & Ordering Standard packaging: 10 vials packed in hard plastic trays with protective outer packing Cartons prepared for export with foam or bubble-wrap to reduce transport damage China-based factory support for wholesale, bulk and OEM relabel projects For pricing, MOQ and custom label options, please contact us directly for a quotation Order processing and dispatch updates are typically provided within 3 business days after payment confirmation Storage & Handling Recommended storage: 28 C in a clean, dry environment, protected from light For longer-term storage, many labs store lyophilized vials in a freezer to maximise stability Reconstituted solutions should be handled using appropriate aseptic techniques under local laboratory guidelines Related Products CJC-1295 Without DAC single peptide kit CJC-1295 (No DAC) 5 mg + Ipamorelin 5 mg combo GHRH/GHRP peptide kit Ipamorelin GH secretagogue peptide kit TB-500 healing & recovery peptide kit BPC-157 tissue-repair peptide kit THIS PRODUCT IS INTENDED AS A RESEARCH CHEMICAL ONLY
Thus our skin is better able to heal from the damage caused by UV rays, environmental toxins, and aging
Balanced Inflammatory Response Quercetin works at the cellular level to help modulate the body's inflammatory signaling pathways, supporting a more balanced recovery response after hard efforts without blunting the adaptations that make training worthwhile
In Wegovys trials, all participants had excess body weight or obesity
Paradoxical real-life underuse of GLP-1 receptor agonists in type 2 diabetes patients with atherosclerotic cardiovascular disease
2019 Nov;29(11):1151-1167
